Tags

Type your tag names separated by a space and hit enter

Hyponatremia in cancer patients.
Tumori 2015 Mar-Apr; 101(2):246-8T

Abstract

Hyponatremia is the most frequent electrolyte disorder in hospitalized patients but also a well known poor prognostic factor in cancer patients. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is often misdiagnosed by oncologist because of difficulties in the interpretation of laboratory tests. Etiology is heterogeneous but the predominant cause is represented by the unbalance between excessive presence of water and serum sodium deficiency. Ectopic production of arginine vasopressin (AVP) develops more frequently in small cell lung cancer but it is not so rare in other malignancies. Neurological impairment may range from subclinical to life-threating symptoms depending by the rate of serum sodium deficiency. Appropriate diagnosis is essential to set a proper therapy. When hyponatremia is caused by SIADH, hypertonic saline infusion is indicated for acute presentation whereas fluid restriction is preferred in case of chronic asymptomatic evolution. Other options include vaptans, vasopressin receptor antagonists, targeted specifically for the correction of euvolemic hyponatremia. The aim of this brief report is to provide concise and specific informations for the management of SIADH in oncology clinical practice.

Authors+Show Affiliations

Department of Medical Oncology, Unit 1, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan - Italy.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

25908038

Citation

Platania, Marco, et al. "Hyponatremia in Cancer Patients." Tumori, vol. 101, no. 2, 2015, pp. 246-8.
Platania M, Verzoni E, Vitali M. Hyponatremia in cancer patients. Tumori. 2015;101(2):246-8.
Platania, M., Verzoni, E., & Vitali, M. (2015). Hyponatremia in cancer patients. Tumori, 101(2), pp. 246-8. doi:10.5301/tj.5000257.
Platania M, Verzoni E, Vitali M. Hyponatremia in Cancer Patients. Tumori. 2015;101(2):246-8. PubMed PMID: 25908038.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hyponatremia in cancer patients. AU - Platania,Marco, AU - Verzoni,Elena, AU - Vitali,Milena, Y1 - 2015/04/16/ PY - 2014/06/12/accepted PY - 2015/4/25/entrez PY - 2015/4/25/pubmed PY - 2015/7/21/medline SP - 246 EP - 8 JF - Tumori JO - Tumori VL - 101 IS - 2 N2 - Hyponatremia is the most frequent electrolyte disorder in hospitalized patients but also a well known poor prognostic factor in cancer patients. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is often misdiagnosed by oncologist because of difficulties in the interpretation of laboratory tests. Etiology is heterogeneous but the predominant cause is represented by the unbalance between excessive presence of water and serum sodium deficiency. Ectopic production of arginine vasopressin (AVP) develops more frequently in small cell lung cancer but it is not so rare in other malignancies. Neurological impairment may range from subclinical to life-threating symptoms depending by the rate of serum sodium deficiency. Appropriate diagnosis is essential to set a proper therapy. When hyponatremia is caused by SIADH, hypertonic saline infusion is indicated for acute presentation whereas fluid restriction is preferred in case of chronic asymptomatic evolution. Other options include vaptans, vasopressin receptor antagonists, targeted specifically for the correction of euvolemic hyponatremia. The aim of this brief report is to provide concise and specific informations for the management of SIADH in oncology clinical practice. SN - 2038-2529 UR - https://www.unboundmedicine.com/medline/citation/25908038/Hyponatremia_in_cancer_patients_ L2 - http://journals.sagepub.com/doi/full/10.5301/tj.5000257?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -